Modulating the HSP90 control over NFκB/NLRP3/Caspase-1 axis is a new therapeutic target in the management of liver fibrosis: Insights into the role of TAS-116 (Pimitespib)
Life Sciences | Vol. 354 | Issue 1 October 2024, 122966 | 2024
DOI: https://doi.org/10.1016/j.lfs.2024.122966